Approximately 40% of colon cancer patients have KRAS mutations, and patients with KRASG13D have a poor prognosis, including susceptibility to metastasis and short survival time, while anti-EGFR therapy offers little benefit.154 Natural product erianin increases the accumulation of ROS and Fe2+ in KRASG13D colon cancer cells, causing cellular lipid peroxidation and mitochondrial morphological changes, thereby inhibiting their migration and invasion. Here, KRAS is linked to malignant colon neoplasm.